Adimab vs Antiverse

Adimab vs Antiverse, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Adimab is on 53/100 and Antiverse on 52/100.

Adimab logo
AdimabAdimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform.
Try Adimab
Antiverse logo
AntiverseAI-powered antibody discovery platform.
Try Antiverse

Where each one leads

Adimab

  • headcount: 139 against 28
  • funding raised: $105M against $15.7M

Antiverse

  • agent readiness: 50/100 against 40/100

At a glance

MeasureAdimabAntiverse
What it isAdimab is a biotechnology company that discovers and develops therapeutic antibodies using its proprietary yeast-based platform.AI-powered antibody discovery platform.
CategoryBiotech, Drug Discovery, Antibody Discovery, Therapeutic AntibodiesBiotechnology, Artificial Intelligence, Drug Discovery, Pharmaceuticals
Sells toBusiness modelB2BB2B
OfferingPlatformPlatform
Founded20072018
HeadquartersLebanon, United StatesLondon, United Kingdom
StatusActiveActive

Size, funding and growth

MeasureAdimabAntiverse
Employees13928
Total funding$105M$15.7M
Latest roundSeries BSeries A
LinkedIn followers8,423Not published

StartupHub scores

Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.

MeasureAdimabAntiverse
StartupHub scoreOur 0-100 rating53/10052/100
Traction60/10051/100
TeamNot published70/100
Search visibility20/1008/100
Quality68/10058/100
Agent readinessHow well an AI agent can read and act on the siteD (40/100)D (50/100)
Domain ratingLink authority, 0-10039/100Not published

Technology

Detected on each public site, so it reflects the marketing stack as well as the product.

MeasureAdimabAntiverse
HostingAWSNot detected
CMSWordPressNot detected
FrameworksJquery, BootstrapNot detected
AnalyticsGoogle Tag Manager, Linkedin InsightNot detected
Support stackHubSpotNot detected

Adimab vs Antiverse: common questions

Which is better, Adimab or Antiverse?

On our 0-100 score Adimab rates higher (53/100 against 52/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.

How do Adimab and Antiverse compare on the numbers?

Adimab leads on headcount (139 against 28), funding raised ($105M against $15.7M). Antiverse leads on agent readiness (50/100 against 40/100).

Read the full Adimab review and pricing or the Antiverse review and pricing. You can also browse other Adimab alternatives we track.